Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib + S-1 Maintenance in HER-2 Negative Gastric Cancer
NCT03950141Phase 2Unknown
- Sponsor
- Beijing Hospital
- Start
- Jul 2017
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib in gastric cancer (GC), sponsored by Beijing Hospital. Primary endpoint: Progression-Free Survival at 1 year. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT03950141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03950141.